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BRIEF REPORT
Effects of Cilostazol and Isosorbide Mononitrate 
on Cerebral Hemodynamics in the LACI-1 
Randomized Controlled Trial
Gordon W. Blair , MRCP; Esther Janssen, MSc; Michael S. Stringer, PhD; Michael J. Thrippleton , PhD;  
Francesca Chappell , PhD; Yulu Shi, PhD; Iona Hamilton, BSc; Katie Flaherty, MSc; Jason P. Appleton , PhD;  
Fergus N. Doubal, PhD; Philip M. Bath , DSc; Joanna M. Wardlaw , MD
BACKGROUND AND PURPOSE: Cerebral small vessel disease—a major cause of stroke and dementia—is associated with 
cerebrovascular dysfunction. We investigated whether short-term isosorbide mononitrate (ISMN) and cilostazol, alone 
or in combination, improved magnetic resonance imaging–measured cerebrovascular function in patients with lacunar 
ischemic stroke.
METHODS: Participants were randomized to ISMN alone, cilostazol alone, both ISMN and cilostazol, or no medication. 
Participants underwent structural, cerebrovascular reactivity (to 6% carbon dioxide) and phase-contrast pulsatility magnetic 
resonance imaging at baseline and after 8 weeks of medication.
RESULTS: Of 27 participants (mean age, 68±7.7; 44% female), 22 completed cerebrovascular reactivity and pulsatility imaging 
with complete datasets. White matter cerebrovascular reactivity increased in the ISMN (β=0.021%/mm Hg [95% CI, 0.003–
0.040]) and cilostazol (β=0.035%/mm Hg [95% CI, 0.014–0.056]) monotherapy groups and in those taking any versus no 
medication (β=0.021%/mm Hg [95% CI, 0.005–0.037]).
CONCLUSIONS: While limited by small sample size, we demonstrate that measuring cerebrovascular function with magnetic 
resonance imaging is feasible in clinical trials and that ISMN and cilostazol may improve cerebrovascular function.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02481323. URL: www.isrctn.com; Unique identifier: 
ISRCTN12580546. URL: www.clinicaltrialsregister.eu; Unique identifier: EudraCT 2015-001953-33.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: cerebral small vessel diseases ◼ cilostazol ◼ cognitive dysfunction ◼ ischemic stroke ◼ magnetic resonance imaging
Cerebral small vessel disease (SVD) is a major cause of stroke and dementia. No specific treatment exists to stop disease progression.1
SVD is associated with reduced cerebrovascular reac-
tivity (CVR2; the ability of blood vessels to increase blood 
flow), more pulsatile blood flow, and impaired cerebrospi-
nal fluid (CSF) dynamics.2,3
Isosorbide mononitrate (ISMN) and cilostazol have 
pharmacological effects that could improve these cere-
brovascular dysfunctions.1 Cilostazol can reduce stroke 
recurrence4 and may reduce cognitive impairment.5 
Glyceryl trinitrate—a shorter-acting nitrate than ISMN—
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We measured CVR, cerebral blood flow, and CSF 
dynamics in patients with lacunar stroke randomly 
assigned to receive ISMN or cilostazol monotherapy, 
combination therapy, or avoid these medications in the 
LACI-1 trial (LACunar Intervention-1).7
METHODS
Data Availability Statement
Access requests can be submitted to the corresponding author.
Participants and Assessments
This study was a substudy of the main LACI-1 trial. LACI- 
1 was a phase IIa, partial factorial, prospective randomized 
open-label blinded end point trial. Our methods are pub-
lished.7 We recruited patients with nondisabling lacunar 
ischemic stroke.
All participants were scanned at randomization and at week 
8 in the cilostazol monotherapy, ISMN monotherapy, and ISMN 
and cilostazol groups and week 3 in the no-medication group 
(after which this group commenced cilostazol and ISMN to 
test the alternative order of starting dual therapy). Medication 
compliance, side effects, and blood pressure (BP) were also 
assessed at each visit.
All participants provided written informed consent. Ethical 
approval was obtained from the Scotland-A Research Ethics 
Committee (Ref: 15/SS/0154).
Intervention
Participants were randomized to ISMN monotherapy, cilostazol 
monotherapy, combination ISMN, and cilostazol or no medica-
tion.7 Dose was titrated to ISMN 25 mg BID and cilostazol 100 
mg BID.7 Medication was taken for 8 weeks. Participants were 
masked to treatment allocation, and investigators assessing 
outcomes including all image analysis were blinded to treat-
ment allocation.7
Imaging
We performed brain scanning using a 1.5T GE MRI scan-
ner (SignaHDxt; General Electric, Milwaukee, WI). Structural 
sequences included T1-weighted, T2-weighted, fluid attenu-
ated inversion recovery, and gradient recalled echo.
CVR Acquisition
During a 12-minute blood oxygen level–dependent magnetic 
resonance imaging (MRI) scan, participants alternated between 
breathing medical air and 6% carbon dioxide (CO2) in air, as is 
published previously.8
Pulsatility Acquisition
Our pulsatility method is published previously.2,3 We used a 
2-dimensional cine phase-contrast sequence to measure flow 
in the internal carotid and vertebral arteries, superior sagittal, 
straight, and transverse venous sinuses, and foramen magnum 
and aqueduct CSF flow.
Image Analysis
We performed CVR analysis by regressing blood oxy-
gen level–dependent signal against end-tidal CO2, with 
CVR expressed as %blood oxygen level–dependent signal 
change/mm Hg change in end-tidal CO2 as published pre-
viously.7,8 We extracted regional measurements of CVR in 
identical regions of the same anatomic structures at the two 
time points. Image analysis was performed by investigators 
blinded to treatment allocation.
Structural and pulsatility analysis methods are pulished.2,3 
Pulsatility index (PI) was calculated as (Flowmaximum− 
Flowminimum)/Flowmean.
Statistical Analysis
We used R, version 1.0.143, for statistical analyses. To exam-
ine the effect of treatment, 2 separate analyses were done. 
First, an intention-to-treat analysis (main article) and second, 
a per-protocol analysis (Supplemental Material) where partici-
pants who had stopped taking medication at the time of the 
follow-up scan were excluded from the treatment groups and 
analyzed as being in the no-medication group. We used mul-
tiple linear regression to assess the effect of treatment groups 
and being on any versus no medication on changes in white 
matter (WM) and gray matter CVR, PI, and CSF flow adjusting 
for age because this is suggested to affect CVR. This analysis 
was repeated and adjusted for systolic BP in place of age to 
examine the confounding effect of BP. To assure normality of 
the residuals and assess heteroscedasticity, we examined QQ 
plots, histograms of residuals, and plots of residual versus fitted 
values to examine.
This analysis was repeated and adjusted for systolic BP 
in place of age to examine the confounding effect of BP. 
Additional analyses were also performed controlling for systolic 
BP change in place of age between baseline and follow-up.
RESULTS
Twenty-seven of the 28 participants recruited to LACI-1 
consented to the MRI substudy. Full CVR data sets were 
obtained in 23 participants and full pulsatility data sets in 
24 (Supplemental Material). The Figure shows the CON-
SORT flowchart.
The mean age of included participants was 68±7.7 
years (range, 53–83 years), Table 1.
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CVR Change After Treatment
WM CVR increased with ISMN and cilostazol mono-
therapy (both P<0.05) and in participants taking any 
versus no trial drug (P<0.05) but not combination 
therapy (Table 2).
There was no increase in gray matter CVR.
Figure. Change in cerebrovascular reactivity (CVR) by treatment group and any vs no medication.
GM indicates gray matter; ISMN, isosorbide mononitrate; and WM, white matter.
Table 1. Patient Characteristics
 All ISMN Cilostazol Combined No medication P value
n 27 7 5 7 8  
Age, y 68±7.7 64.6±7.1 74.4±9.2 67.9±4.3 67.0±8.2 0.34
Sex, female 12 (44.4%) 2 (28.6%) 4 (80%) 3 (42.9%) 3 (37.5%) 0.33
Systolic BP, mm Hg 141.9±19.3 142.3±22.8 142.2±17.0 146.9±23.6 137.1±15.7 0.82
Treated hypertension 21 (77.8%) 6 (85.7%) 5 (100%) 4 (57.1%) 6 (75%) 0.52
WMH volume (percentage of intra-
cranial volume), median (IQR)
1.1 (0.5–1.6) 0.5 (0.3–1.2) 1.2 (1.2–1.7) 0.8 (0.6–1.0) 1.3 (0.6–2.1) 0.35
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Pulsatility Change After Treatment
Superior sagittal sinus PI increased with cilostazol alone. 
Vertebral artery PI decreased with ISMN alone (Table 2). 
CSF pulsatility did not change.
DISCUSSION
Over an 8-week period, treatment with ISMN or cilostazol 
alone, or any drug versus no drug, increased WM but not gray 
matter CVR. Effects on pulsatility varied: ISMN decreased PI 
in the vertebral arteries; however, cilostazol increased supe-
rior sagittal sinus PI, which could be secondary to cilostazol 
increasing heart rate.7 No changes in CSF flow dynamics 
were detected. Combination therapy did not have the effect 
of monotherapy although CVR in WM increased in partici-
pants taking any versus no medication, which includes those 
allocated dual therapy. Small numbers in each treatment 
group and participants finding it difficult to reach maximum 
dose of both drugs in combination means this is more likely 
sample size related and the true difference between effects 
of monotherapy versus combination remains undetermined.
Prior studies have measured medication effects on 
resting cerebral blood flow in similar patient populations. 
The DANTE study (Discontinuation of Antihypertensives in 
the Elderly) showed no change in MRI-measured cerebral 
blood flow after antihypertensive medication withdrawal, 
compared with continuing antihypertensives.9 The PRE-
SERVE trial (Prevention of Serious Adverse Events Fol-
lowing Angiography) showed no change in MRI-measured 
cerebral blood flow with more versus less intensive BP low-
ering in patients with stroke-related moderate-to-severe 
SVD.10 Others have demonstrated pravastatin, atorvas-
tatin, perindopril, and vinpocetine all increase transcranial 
Doppler-measured vasoreactivity.11–15 The changes in CVR 
we demonstrated were independent of any change in sys-
tolic BP induced by medication, adding further evidence 
that changes in blood flow and vascular function in older 
individuals with SVD have a complex relationship with 
BP. We have previously demonstrated stronger associa-
tions of WM than gray matter CVR with SVD.2 WM may be 
differentially more impaired in SVD and thus more ame-
nable to a detectable pharmacological improvement.
Lack of improvement in PI could reflect that modifica-
tion of vascular stiffening requires longer treatment. Cilo-
stazol has previously been shown to decrease PI after 90 
days in patients with lacunar infarction.16
Limitations
The sample is small. However, a primary aim of LACI-1 
was to establish feasibility of the drug regimen to inform 
a larger trial (LACI-2; ISRCTN14911850) and second-
arily to gather efficacy and safety data.7,17
The randomization was imperfect, as in the overall 
main trial,7 with the cilostazol-only group being older.
Conclusions
We demonstrated feasibility of cerebrovascular function 
MRI in a clinical trial of lacunar ischemic stroke and SVD 
and detected changes in CVR and pulsatility that sup-
port the positive modification of cerebrovascular function 
by existing medications. Larger studies over longer time 
periods will assess whether these improvements trans-
late into clinical benefits.
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Table 2. Associations Between Change in White Matter CVR, Intracranial Pulsatility, and Treatment
 Treatment group Any medication
White matter CVR ISMN β=0.021 (0.003 to 0.040), P=0.027 β=0.021 (0.005–0.037), P=0.014
Cilostazol β=0.035 (0.014 to 0.056), P=0.003
Combined β=0.011 (−0.04 to 0.047), P=0.222
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Cilostazol β=−0.107 (−0.510 to 0.295), P=0.583
Combined β=−0.103 (−0.439 to 0.234), P=0.531
Multiple regression analysis adjusted for age. Standardized β-coefficient, 95% CI, and P value. The no-medication group is the reference group 
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